Johnson & Johnson $JNJ Stock Bought by Market Street Wealth Management Advisors LLC

Market Street Wealth Management Advisors LLC raised its stake in Johnson & Johnson (NYSE:JNJ) by 272.3% in the third quarter, HoldingsChannel reports. The fund owned 4,334 shares of the company’s stock after purchasing an additional 3,170 shares during the period. Market Street Wealth Management Advisors LLC’s holdings in Johnson & Johnson were worth $1,147,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Outlook Capital Management LLC purchased a new stake in Johnson & Johnson during the second quarter worth $28,000. Matrix Trust Co boosted its stake in shares of Johnson & Johnson by 56.2% during the 2nd quarter. Matrix Trust Co now owns 150 shares of the company’s stock worth $38,000 after acquiring an additional 54 shares in the last quarter. Montgomery Financial Services LLC acquired a new stake in shares of Johnson & Johnson during the 2nd quarter valued at about $43,000. Hyposwiss Advisors SA purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at about $42,000. Finally, Polaris Financial Partners acquired a new position in Johnson & Johnson in the 3rd quarter worth about $56,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: New two-year Phase 3 data for ICOTYDE (icotrokinra) showed sustained psoriasis benefits in adults and adolescents, with nearly three-quarters achieving clear or almost clear skin by two years and a favorable safety profile. The results strengthen the drug’s potential as a long-term growth product. ICOTYDE long-term psoriasis data
• Positive Sentiment: Johnson & Johnson’s cancer pipeline also received support from data showing that the Tecvayli-and-Talvey combination reduced the relative risk of disease progression or death by 89% and the risk of death by 62% in relapsed or refractory multiple myeloma. Cancer treatment advances
• Positive Sentiment: Guggenheim reaffirmed its Buy rating and assigned a $287 price target, while Morgan Stanley also issued a Buy rating. These recommendations indicate continued confidence in JNJ’s earnings durability, pipeline and defensive characteristics. Guggenheim Buy rating Morgan Stanley Buy rating
• Neutral Sentiment: Investors are awaiting third-quarter results. The company’s latest quarter beat estimates, with revenue up 6.6% year over year, and management raised 2026 guidance, but the upcoming report must confirm that momentum.
• Negative Sentiment: JNJ faces a major patent-cliff risk as exclusivity for cancer drugs Imbruvica and Darzalex expires over the coming years. The resulting revenue pressure makes pipeline execution and acquisitions increasingly important. Johnson & Johnson patent cliff
• Negative Sentiment: At roughly 30 times earnings, JNJ trades at a premium to slower-growth peers. Biosimilar competition, MedTech softness and ongoing talc litigation add to concerns about whether the current valuation fully reflects future growth.

Insider Activity

In other news, EVP Vanessa Broadhurst sold 23,054 shares of the firm’s stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the completion of the sale, the executive vice president owned 23,003 shares in the company, valued at $5,779,963.81. This trade represents a 50.06% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Elizabeth Forminard sold 15,918 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total value of $4,090,926.00. Following the completion of the transaction, the executive vice president owned 16,994 shares in the company, valued at $4,367,458. This represents a 48.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 87,569 shares of company stock worth $23,064,544. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $256.85 on Friday. Johnson & Johnson has a one year low of $184.66 and a one year high of $281.07. The stock has a market cap of $618.99 billion, a PE ratio of 29.76, a P/E/G ratio of 2.59 and a beta of 0.21. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The stock has a 50 day moving average price of $265.73 and a 200 day moving average price of $248.93.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The company had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. During the same quarter in the previous year, the company posted $2.77 earnings per share. The firm’s revenue for the quarter was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Equities research analysts expect that Johnson & Johnson will post 11.3 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were paid a dividend of $1.34 per share. The ex-dividend date of this dividend was Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a yield of 2.1%. Johnson & Johnson’s payout ratio is 62.11%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Johnson Rice reissued a “buy” rating on shares of Johnson & Johnson in a report on Monday, August 3rd. The Goldman Sachs Group reiterated a “buy” rating and issued a $282.00 price objective on shares of Johnson & Johnson in a report on Thursday, July 16th. Citigroup raised their target price on Johnson & Johnson from $298.00 to $303.00 and gave the company a “buy” rating in a research report on Monday. HSBC boosted their price target on Johnson & Johnson from $290.00 to $320.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Finally, Royal Bank Of Canada raised their price objective on Johnson & Johnson from $287.00 to $290.00 and gave the company an “outperform” rating in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $276.22.

Johnson & Johnson Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.